Shanghai, China, May 7, 2024 – Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, presents data of multiple novel AAV gene therapy programs at the American Society of Gene and Cel...
Skyline Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Phase I/IIa clinical trial of SKG0106.